Prelude TherapeuticsPRLD +1.63%26 EV-to-OCF is -7.62 as of Jul. 07, 2026. GuruFocus rates PRLD with a GF Score™ of 26/100. The stock has 6 warning signs investors should review. Among 1,409 Biotechnology companies, Prelude Therapeutics ranks better than 63.09% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Prelude Therapeutics's Enterprise Value is $333.60 Mil.
Prelude Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-43.76 Mil. Therefore, Prelude Therapeutics's EV-to-OCF for today is -7.62.
The historical rank and industry rank for Prelude Therapeutics's EV-to-OCF or its related term are showing as below:
PRLD'
s EV-to-OCF Range Over the Past 10 Years
Min: -7.81 Med: -0.17 Max: 0.71
Current: -7.62
During the past 8 years, the highest EV-to-OCF of Prelude Therapeutics was 0.71. The lowest was -7.81. And the median was -0.17.
PRLD's EV-to-OCF is ranked better than 63.09% of 1409
companies
in the Biotechnology industry
Industry Median: -3.62
vs PRLD: -7.62
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Prelude Therapeutics's PE Ratio (TTM) for today is calculated as:
Prelude Therapeutics's share price for today is $4.99.
Prelude Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Prelude Therapeutics EV-to-OCF Related Terms
Prelude Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Prelude Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Prelude Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prelude Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Prelude Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Prelude Therapeutics's EV-to-OCF falls into.
Prelude Therapeutics's current Enterprise Value is $333.60 Mil.
Prelude Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-43.76 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prelude Therapeutics (PRLD) has a EV-to-OCF of -7.62 as of Jul. 07, 2026. According to the industry distribution chart, Prelude Therapeutics ranks #520 out of 1409 companies in the Biotechnology industry, placing it in the top 36.9%.
Is Prelude Therapeutics' EV-to-OCF too high?
Prelude Therapeutics' current EV-to-OCF is -7.62. Based on the distribution chart, Prelude Therapeutics ranks #520 out of 1409 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Prelude Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Prelude Therapeutics' EV-to-OCF compare to DMAC and RCKT?
According to the Biotechnology industry distribution chart, Prelude Therapeutics ranks #520 out of 1409 companies for EV-to-OCF. This puts Prelude Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Prelude Therapeutics's current EV-to-OCF is -7.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prelude Therapeutics stock overvalued right now?
Prelude Therapeutics (PRLD) has a current EV-to-OCF of -7.62. The current EV-to-OCF is -7.62. Prelude Therapeutics' overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Prelude Therapeutics (PRLD), the current EV-to-OCF is -7.62 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
26GF Score
Get the complete analysis for PRLD
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRLD has been successfully added to your 
